Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
OPERATING ACTIVITIES    
Net (loss) income $ 1,033 $ 6,662
Adjustments to reconcile net income to net cash provided by operating activities:    
Provision for doubtful accounts (99) 534
Depreciation 7,705 7,267
Loss on disposal of and reserve adjustments for medical equipment 848 150
Gain on sale of medical equipment (1,588) (2,949)
Amortization of intangible assets 3,264 3,225
Amortization of deferred debt issuance costs 132 13
Stock-based compensation 4,962 1,222
Deferred income taxes (875) 16
Changes in assets - (increase)/decrease:    
Accounts receivable 217 (1,490)
Inventories (630) (1,074)
Other current assets 251 75
Other assets (102) (114)
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (513) (869)
NET CASH PROVIDED BY OPERATING ACTIVITIES 14,605 12,668
INVESTING ACTIVITIES    
Acquisition of business (7,650) 0
Purchase of medical equipment (9,645) (11,955)
Purchase of property and equipment (607) (865)
Proceeds from sale of medical equipment, property and equipment 2,214 3,870
NET CASH USED IN INVESTING ACTIVITIES (15,688) (8,950)
FINANCING ACTIVITIES    
Principal payments on long-term debt (69,306) (35,458)
Cash proceeds from long-term debt 61,654 31,861
Debt issuance costs (386) 0
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (1,141) (1,269)
Cash proceeds from stock plans 779 190
Common stock - issued 0 250
NET CASH USED IN FINANCING ACTIVITIES (8,400) (4,426)
Net change in cash and cash equivalents (9,483) (708)
Cash and cash equivalents, beginning of period 9,648 2,647
Cash and cash equivalents, end of period $ 165 $ 1,939